| Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer K Moore, N Colombo, G Scambia, BG Kim, A Oaknin, M Friedlander, ... New England Journal of Medicine 379 (26), 2495-2505, 2018 | 2560 | 2018 |
| Endometrial cancer P Morice, A Leary, C Creutzberg, N Abu-Rustum, E Darai The Lancet 387 (10023), 1094-1108, 2016 | 2020 | 2016 |
| Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial RL Coleman, AM Oza, D Lorusso, C Aghajanian, A Oaknin, A Dean, ... The Lancet 390 (10106), 1949-1961, 2017 | 1683 | 2017 |
| Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial EM Swisher, KK Lin, AM Oza, CL Scott, H Giordano, J Sun, GE Konecny, ... The lancet oncology 18 (1), 75-87, 2017 | 1193 | 2017 |
| Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study HC Chung, W Ros, JP Delord, R Perets, A Italiano, R Shapira-Frommer, ... Journal of Clinical Oncology 37 (17), 1470-1478, 2019 | 879 | 2019 |
| Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: impact on prognosis and benefit from adjuvant therapy A León-Castillo, SM De Boer, ME Powell, LR Mileshkin, HJ Mackay, ... Journal of Clinical Oncology 38 (29), 3388-3397, 2020 | 568 | 2020 |
| Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative E Stelloo, T Bosse, RA Nout, HJ MacKay, DN Church, HW Nijman, ... Modern pathology 28 (6), 836-844, 2015 | 452 | 2015 |
| Ovarian cancer: a heterogeneous disease M Kossaï, A Leary, JY Scoazec, C Genestie Pathobiology 85 (1-2), 41-49, 2018 | 387 | 2018 |
| ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer RE Miller, A Leary, CL Scott, V Serra, CJ Lord, D Bowtell, DK Chang, ... Annals of Oncology 31 (12), 1606-1622, 2020 | 346 | 2020 |
| SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomas F Le Loarer, S Watson, G Pierron, VT de Montpreville, S Ballet, N Firmin, ... Nature genetics 47 (10), 1200-1205, 2015 | 318 | 2015 |
| Oncological outcomes after fertility-sparing surgery for cervical cancer: a systematic review E Bentivegna, S Gouy, A Maulard, C Chargari, A Leary, P Morice The Lancet Oncology 17 (6), e240-e253, 2016 | 285 | 2016 |
| Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo … S Banerjee, KN Moore, N Colombo, G Scambia, BG Kim, A Oaknin, ... The Lancet Oncology 22 (12), 1721-1731, 2021 | 278 | 2021 |
| Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated … AM Oza, AV Tinker, A Oaknin, R Shapira-Frommer, IA McNeish, ... Gynecologic oncology 147 (2), 267-275, 2017 | 261 | 2017 |
| Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label … E Pujade-Lauraine, K Fujiwara, JA Ledermann, AM Oza, R Kristeleit, ... The Lancet Oncology 22 (7), 1034-1046, 2021 | 247 | 2021 |
| Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment R Belkhir, S Le Burel, L Dunogeant, A Marabelle, A Hollebecque, B Besse, ... Annals of the rheumatic diseases 76 (10), 1747-1750, 2017 | 247 | 2017 |
| Overall survival with maintenance olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: the SOLO1/GOG 3004 trial P DiSilvestro, S Banerjee, N Colombo, G Scambia, BG Kim, A Oaknin, ... Journal of Clinical Oncology 41 (3), 609-617, 2023 | 239 | 2023 |
| The PI3K/Akt/mTOR pathway in ovarian cancer: therapeutic opportunities and challenges B Cheaib, A Auguste, A Leary Chinese journal of cancer 34, 4-16, 2015 | 233 | 2015 |
| Mucinous ovarian carcinoma P Morice, S Gouy, A Leary New England Journal of Medicine 380 (13), 1256-1266, 2019 | 192 | 2019 |
| Neoadjuvant chemotherapy (NACT) increases immune infiltration and programmed death-ligand 1 (PD-L1) expression in epithelial ovarian cancer (EOC) SJL Mesnage, A Auguste, C Genestie, A Dunant, E Pain, F Drusch, ... Annals of oncology 28 (3), 651-657, 2017 | 185 | 2017 |
| Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study … PM Morice, A Leary, C Dolladille, B Chrétien, L Poulain, ... The Lancet Haematology 8 (2), e122-e134, 2021 | 183 | 2021 |
